Gadolinium (Gadolinium-Based Contrast Agents)

Gadolinium is a rare earth metal used in gadolinium-based contrast agents (GBCAs), dyes injected into a vein before certain MRI scans to sharpen images of blood vessels, tumors, and inflammation. Brand names include Magnevist, Omniscan, MultiHance, Dotarem, and others. Millions of MRI scans each year use them.

The agents were designed to be flushed out through the kidneys, but research showed that traces can remain. On December 19, 2017, the FDA required a new class warning for all gadolinium-based contrast agents, noting that gadolinium can remain in patients' bodies, including the brain, for months to years, and it required a patient Medication Guide. The FDA said linear agents are retained more, and longer, than macrocyclic agents. At the same time, it said retention had not been directly linked to harmful effects in patients with normal kidney function and that the benefits of approved agents continue to outweigh the risks.

A separate, well-established risk is nephrogenic systemic fibrosis, a rare but serious thickening of the skin and organs that can occur in patients with severe kidney disease who receive GBCAs. That risk drove an earlier wave of lawsuits. More recent cases have alleged "gadolinium deposition disease," with symptoms such as pain, skin changes, and cognitive problems in people with normal kidneys. These claims face a major hurdle because regulators have not recognized a proven link, so causation is heavily contested.

If you believe a contrast agent harmed you, request your imaging records, which should list the agent and dose, and any testing for retained gadolinium. Our guides on class actions versus mass torts and lawsuit investigations explain how claims like this develop.